PAUL HOPKINS to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications PAUL HOPKINS has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.607
-
Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. J Clin Lipidol. 2019 Nov - Dec; 13(6):970-978.
Score: 0.445
-
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations. Am J Cardiol. 2020 03 15; 125(6):880-886.
Score: 0.113
-
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 Mar - Apr; 12(2):390-396.e8.
Score: 0.025
-
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1338-1346.e7.
Score: 0.024